Recombinant human leukocyte interferon‐α 2b stimulates the synthesis and release of a 90k tumor‐associated antigen in human breast cancer cells

Authors:

Abstract
We have previously reported the production of a new monoclonal antibody (MAb) (SP‐2) recognizing a 90‐kDa tumorassociated antigen, termed 9OK, which is increased in the serum of many cancer patients. Treatment of CG5 human breast cancer cells with recombinant interferon‐α 2b (rlFN‐α 2b) can increase the synthesis and release, in culture medium, of the 90K. The effect of rIFN‐α 2b was dose‐related and occurred at concentrations which did not affect cell proliferation. The increase of 90K expression was due to de novo protein synthesis since cycloheximide, added within 3 hr of the beginning of rIFN‐α 2b stimulation treatment, completely abolished the effect of rlFN‐α 2b. The stimulatory effect of rIFN‐α 2b was already evident after 24 hr treatment. Finally, an increase in serum 90K levels was observed in 3 patients with advanced breast cancer receiving a short course of rIFN‐α 2b (Intron A). No effect of rIFN‐α 2b was seen in 3 normal women. The ability of rIFN‐α 2b to increase the synthesis and release of 9OK both in vitro and in vivo may be of clinical importance in the early detection of tumors.

This publication has 10 references indexed in Scilit: